Immune Recombinant Proteins
Immune checkpoint recombinant proteins are engineered molecules designed to modulate immune responses. These proteins are critical tools in research and therapeutic development, particularly in oncology and immunology. Immune checkpoints, such as CTLA-4, PD-1, and their ligands (CD80/CD86 and PD-L1, respectively), play pivotal roles in maintaining immune homeostasis and preventing autoimmunity.
Content
Immune checkpoint recombinant proteins are synthesized in expression systems such as Escherichia coli, mammalian cells (e.g., HEK293, CHO), or yeast to ensure proper folding and post-translational modifications. These proteins can include full-length molecules, extracellular domains, or fusion constructs with tags (e.g., His, Fc) for enhanced detection or purification.
Applications
- Cancer Immunotherapy Development:
- Facilitates the screening of monoclonal antibodies and small molecules targeting immune checkpoint pathways.
- Supports preclinical evaluation of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4).
- Basic Immunological Research:
- Used in binding assays to decipher interactions between receptors and ligands.
- Enables structural and functional studies to elucidate checkpoint mechanisms.
- Drug Discovery and Screening:
- Essential in high-throughput screening platforms for novel immunomodulatory agents.
- Supports in vitro assays to test drug efficacy and specificity.
The use of immune checkpoint recombinant proteins is expanding rapidly, driven by their importance in understanding immune regulation and their central role in the next generation of immunotherapeutic strategies.
|
|
|
|
|
|